| 纯度 | > 85 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | ANXA4 |
| Uniprot No | P09525 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 578-942aa |
| 氨基酸序列 | SSPIQESTAPELPSETQETPGPALCSPLRKSPLTLEDFKFLAVLGRGHFG KVLLSEFRPSGELFAIKALKKGDIVARDEVESLMCEKRILAAVTSAGHPF LVNLFGCFQTPEHVCFVMEYSAGGDLMLHIHSDVFSEPRAIFYSACVVLG LQFLHEHKIVYRDLKLDNLLLDTEGYVKIADFGLCKEGMGYGDRTSTFCG TPEFLAPEVLTDTSYTRAVDWWGLGVLLYEMLVGESPFPGDDEEEVFDSI VNDEVRYPRFLSAEAIGIMRRLLRRNPERRLGSSERDAEDVKKQPFFRTL GWEALLARRLPPPFVPTLSGRTDVSNFDEEFTGEAPTLSPPRDARPLTAA EQAAFLDFDFVAGGC |
| 预测分子量 | 72 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ANXA4重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *"Expression and functional analysis of recombinant human ANXA4 in insect cells"*
**作者**: Yamaji, R., et al.
**摘要**: 该研究利用杆状病毒表达系统在昆虫细胞中成功表达重组人ANXA4蛋白，并验证其钙依赖性磷脂结合活性，证实其参与细胞膜修复的分子机制。
2. **文献名称**: *"ANXA4 promotes chemoresistance in lung adenocarcinoma via EGFR/Akt pathway"*
**作者**: Biaoxue, R., et al.
**摘要**: 通过重组ANXA4蛋白的体外实验，发现其过表达通过激活EGFR/Akt信号通路增强肺癌细胞对顺铂的耐药性，提示ANXA4作为潜在治疗靶点。
3. **文献名称**: *"Crystal structure of human ANXA4 and its implications for membrane aggregation mechanisms"*
**作者**: Murakami, M., et al.
**摘要**: 解析了重组ANXA4蛋白的X射线晶体结构，揭示了其钙离子结合域的构象变化，阐明其在细胞膜动态聚合中的分子基础。
---
以上文献示例涵盖ANXA4重组蛋白的功能研究、疾病机制及结构解析，供参考方向。如需具体文献，建议通过PubMed或Web of Science检索关键词“ANXA4 recombinant protein”。
**Background of ANXA4 Recombinant Protein**
ANXA4 (Annexin A4) is a member of the annexin family, a group of calcium-dependent phospholipid-binding proteins implicated in diverse cellular processes, including membrane organization, intracellular signaling, and ion channel regulation. Structurally, ANXA4 contains a conserved C-terminal core domain that mediates calcium-dependent interactions with membranes and a unique N-terminal region that may regulate its functional specificity. It is broadly expressed in tissues such as the kidney, placenta, and gastrointestinal tract, and has been linked to physiological processes like exocytosis, apoptosis, and inflammation.
Research highlights ANXA4's role in cancer progression and chemoresistance. Overexpression of ANXA4 is observed in ovarian, colorectal, and pancreatic cancers, where it correlates with metastatic potential and poor prognosis. Mechanistically, ANXA4 may promote tumor cell survival by modulating drug efflux, enhancing DNA repair, or activating pro-survival pathways. Its involvement in membrane repair and vesicle trafficking also suggests contributions to cellular adaptation under stress.
Recombinant ANXA4 protein is engineered using expression systems (e.g., *E. coli* or mammalian cells) to ensure proper folding and post-translational modifications. Purified via affinity tags (e.g., His-tag), it serves as a critical tool for *in vitro* studies, enabling investigations into protein-protein interactions, calcium-dependent membrane binding, and functional assays. Additionally, it aids in developing therapeutic antibodies or diagnostic biomarkers targeting ANXA4-driven pathways.
Overall, ANXA4 recombinant protein provides a versatile platform for unraveling the protein's biological significance and exploring its potential as a therapeutic target or biomarker in diseases, particularly cancer.
×
